IL1B and congenital rubella syndrome: (30) Another murine model of CRS developing after anti-CD19 CAR T cell therapy for B-ALL also demonstrated that CRS severity was mediated by IL-6, IL-1, and nitric oxide production from recipient macrophages rather than directly from the CAR T cells themselves (31).